Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows
Benzinga Newsdesk 1 month ago
News
Ivonescimab Reduced the Risk of Death by 27% Compared to PembrolizumabHARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 MonthsPD-L1 High Expression Subgroup: Hazard Ratio = 0.58Summit is Conducting
- Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab
- HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months
- PD-L1 High Expression Subgroup: Hazard Ratio = 0.58
- Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC